Lake Street Capital Begins Coverage on InfuSystem (NYSE:INFU)

Lake Street Capital started coverage on shares of InfuSystem (NYSE:INFU) in a report released on Monday, MarketBeat reports. The brokerage issued a buy rating and a $15.00 price target on the stock.

Separately, Roth Capital started coverage on shares of InfuSystem in a research note on Tuesday, July 22nd. They set a “buy” rating and a $12.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Strong Buy” and a consensus target price of $13.33.

InfuSystem Stock Performance

InfuSystem stock opened at $10.25 on Monday. The company has a 50 day moving average price of $8.70 and a 200-day moving average price of $6.67. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. InfuSystem has a fifty-two week low of $4.61 and a fifty-two week high of $11.04. The company has a market capitalization of $209.37 million, a PE ratio of 170.86 and a beta of 1.82.

Insider Transactions at InfuSystem

In related news, Director Scott Shuda sold 5,752 shares of InfuSystem stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $9.67, for a total transaction of $55,621.84. Following the transaction, the director directly owned 94,000 shares of the company’s stock, valued at $908,980. This trade represents a 5.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 11.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On InfuSystem

Several institutional investors have recently bought and sold shares of INFU. Northern Trust Corp increased its holdings in InfuSystem by 7.7% during the fourth quarter. Northern Trust Corp now owns 186,741 shares of the company’s stock valued at $1,578,000 after buying an additional 13,333 shares during the period. BNP Paribas Financial Markets grew its holdings in InfuSystem by 67.9% in the fourth quarter. BNP Paribas Financial Markets now owns 6,844 shares of the company’s stock worth $58,000 after purchasing an additional 2,768 shares during the last quarter. Bank of America Corp DE grew its holdings in InfuSystem by 74.0% in the fourth quarter. Bank of America Corp DE now owns 23,694 shares of the company’s stock worth $200,000 after purchasing an additional 10,074 shares during the last quarter. Deutsche Bank AG grew its holdings in InfuSystem by 148.3% in the fourth quarter. Deutsche Bank AG now owns 27,671 shares of the company’s stock worth $234,000 after purchasing an additional 16,526 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in InfuSystem by 6.3% in the fourth quarter. Millennium Management LLC now owns 76,419 shares of the company’s stock worth $646,000 after purchasing an additional 4,532 shares during the last quarter. 71.13% of the stock is owned by hedge funds and other institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.